Exploration on the construction of a bladder cancer prognostic model based on disulfidptosis-related lncRNAs and its clinical significance

被引:0
|
作者
Hu, Xian-Cun [1 ]
Yu, Qi-Ying [2 ]
Ding, Hai-Ping [1 ]
Xiao, Feng [3 ]
Gu, Chun-Yan [3 ]
机构
[1] Nantong Univ, Med Sch, Nantong 226007, Jiangsu, Peoples R China
[2] Nantong Univ, Nantong Tumor Hosp, Affiliated Tumor Hosp, Canc Res Ctr, Nantong 226361, Jiangsu, Peoples R China
[3] Nantong Univ, Nantong Peoples Hosp 3, Affiliated Nantong Hosp 3, Dept Pathol, Nantong 226006, Jiangsu, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Bladder cancer; Disulfidptosis; lncRNA; TCGA database; Prognosis;
D O I
10.1038/s41598-024-78481-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Disulfidptosis is a novel programmed cell death mode that has been reported to play a role in oncogenesis. Increasing evidences suggest that the long non-coding RNAs (lncRNAs) play crucial roles in the initiation and progression of bladder cancer (BLCA). However, the role and prognostic value of disulfidptosis-related lncRNAs in BLCA remain unknown.The aim of this study was to construct and validate a disulfidptosis-related lncRNA risk model for predicting the prognosis of BLCA patients. A risk model consisting of 5 disulfidptosis-related lncRNAs was developed to predict the prognosis of BLCA patients. The overall survival (OS) of BLCA patients in the high-risk group was significantly shorter than that in the low-risk group (P < 0.05). The effectiveness of this model was validated using the receiver operating characteristic (ROC) curve analysis, and this model proved superior in prognostic accuracy compared with other clinical features. Furthermore, the tumor immune dysfunction and exclusion (TIDE) score in the high-risk group was significantly higher than that in the low-risk group, suggesting that the high-risk group had a less favorable response to immunotherapy. Simultaneously, patients in the low-risk group exhibited significantly higher sensitivity to CTLA-4 monoclonal antibody therapy compared to those in the high-risk group, suggesting potential benefits of immunotherapy for patients in the low-risk group. The combination of high risk and low tumor mutational burden (TMB) could further shortened the OS of BLCA patients. Lastly, the drug sensitivity analysis revealed that the BLCA cells in the high-risk group showed an increased sensitivity to cisplatin, sunitinib, cetuximab, axitinib, docetaxel, saracatinib, vinblastine and pazopanib compared with those in the low-risk group. According to the Quantitative real time PCR results, we found that five lncRNAs of the risk model were more highly expressed in BCa cell lines than human immortalized uroepithelial cell line. The disulfidptosis-related lncRNA risk model has a valuable effect in assessing the prognosis of BLCA patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma
    Sun, Zhou
    Wang, Jie
    Fan, Zheqi
    Yang, Yongjin
    Meng, Xiangdi
    Ma, Zhaosen
    Niu, Jiqiang
    Guo, Rui
    Tran, Lisa Jia
    Zhang, Jing
    Jiang, Tianxiao
    Liu, Yunfei
    Yang, Qiwei
    Ma, Baoluo
    JOURNAL OF GENE MEDICINE, 2024, 26 (01)
  • [22] Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer
    Mulati, Yelisudan
    Lai, Cong
    Luo, Jiawen
    Hu, Jintao
    Xu, Xiaoting
    Kong, Degeng
    Xiao, Yunfei
    Liu, Cheng
    Xu, Kewei
    BMC CANCER, 2024, 24 (01)
  • [23] Disulfidptosis-related signature elucidates the prognostic, immunologic, and therapeutic characteristics in ovarian cancer
    Cong, Yunyan
    Cai, Guangyao
    Ding, Chengcheng
    Zhang, Han
    Chen, Jieping
    Luo, Shiwei
    Liu, Jihong
    FRONTIERS IN GENETICS, 2024, 15
  • [24] Development of a Risk Model and Genotyping Patterns Based on Disulfidptosis-Related lncRNAs to Predict Prognosis and Immune Landscape in Osteosarcoma
    Zhang, Ke
    Lu, Shenyi
    Jiang, Mingyang
    Zou, Xiaochong
    Chen, Chuanliang
    Lan, Yuanyuan
    Zhao, Huaan
    Ma, Ruilan
    Yan, Haiwei
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2024, 29 (05):
  • [25] Prognosis Prediction of Disulfidptosis-Related Genes in Bladder Cancer and a Comprehensive Analysis of Immunotherapy
    Jiang, Chonghao
    Xiao, Yonggui
    Xu, Danping
    Huili, Youlong
    Nie, Shiwen
    Li, Hubo
    Guan, Xiaohai
    Cao, Fenghong
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2023, 33 (06): : 73 - 86
  • [26] Identification of a prognostic disulfidptosis-related gene signature in hepatocellular cancer
    Zhu, Jinhong
    Wu, Yan
    Ji, Pengyu
    Qi, Jun
    Yang, Xuekun
    Pocha, Christine
    Tustumi, Francisco
    de Castria, Tiago Biachi
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1647 - 1656
  • [27] Pan-cancer analysis of the disulfidptosis-related gene RPN1 and its potential biological function and prognostic significance in gliomas
    Zong, Yan
    Zhu, Ankang
    Liu, Peipei
    Fu, Peiji
    Li, Yinuo
    Chen, Shuai
    Gao, Xingcai
    HELIYON, 2024, 10 (11)
  • [28] Construction of stomach adenocarcinoma prognostic signature based on anoikis-related lncRNAs and clinical significance
    Lu, Lina
    Yu, Min
    Huang, Wei
    Chen, Hui
    Jiang, Guofa
    Li, Gangxiu
    LIBYAN JOURNAL OF MEDICINE, 2023, 18 (01)
  • [29] Crosstalk among disulfidptosis-related lncRNAs in lung adenocarcinoma reveals a correlation with immune profile and clinical prognosis
    Liu, Shifeng
    Wang, Song
    Guo, Jian
    Wang, Congxiao
    Zhang, Hao
    Lin, Dongliang
    Wang, Yuanyong
    Hu, Xiaokun
    NON-CODING RNA RESEARCH, 2024, 9 (03): : 772 - 781
  • [30] Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer
    Chen, Sheng
    Li, Xiangrong
    Ao, Wen
    BMC WOMENS HEALTH, 2024, 24 (01)